Comparison
Omega-3 (DHA/EPA) vs Memantine (Namenda)
Omega-3 (DHA/EPA)
Essential fatty acids critical for brain structure and function. DHA comprises ~40% of brain polyunsaturated fatty acids.
Memantine (Namenda)
Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease. Reduces glutamate excitotoxicity while preserving normal signaling.
| Field | Omega-3 (DHA/EPA) | Memantine (Namenda) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–3000mg | 5–20mg |
| Half-life | 24h | 70h |
| Onset | – | 180min |
| Evidence | EVIDENCEA | EVIDENCEA |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 5200 | 4200 |
The comparison in plain English
Auto-generated from dataOmega-3 (DHA/EPA) and Memantine (Namenda) are both in the neuroprotective category respectively. Omega-3 (DHA/EPA) Essential fatty acids critical for brain structure and function. Memantine (Namenda) Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease.
Bottom line
Omega-3 (DHA/EPA) (evidence A, safety 5/5) matches the evidence base of Memantine (Namenda) (evidence A, safety 4/5). Omega-3 (DHA/EPA) has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Omega-3 (DHA/EPA) if
Omega-3 (DHA/EPA) is the better fit when your goal aligns with its mechanism (DHA (docosahexaenoic acid) is a structural component of neuronal cell membranes, maintaining fluidity and supporting receptor function) and the dose range (1000–3000mg) suits your protocol. Half-life is 24h.
Choose Memantine (Namenda) if
Memantine (Namenda) is the better fit when your goal aligns with its mechanism (Uncompetitive NMDA receptor antagonist, blocks the NMDA channel only when it's pathologically over-activated, sparing normal signaling) and the dose range (5–20mg) suits your protocol. Half-life is 70h.